CytomX Therapeutics Ownership
| CTMX Stock | USD 1.19 0.02 1.71% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 83 M | Current Value 85 M | Avarage Shares Outstanding 46.4 M | Quarterly Volatility 22.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CytomX |
CytomX Stock Ownership Analysis
About 72.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. For more info on CytomX Therapeutics please contact Sean DPHIL at 650 515 3185 or go to https://www.cytomx.com.Besides selling stocks to institutional investors, CytomX Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CytomX Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CytomX Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
CytomX Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Only 1.0% of CytomX Therapeutics are currently held by insiders. Unlike CytomX Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CytomX Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CytomX Therapeutics' insider trades
CytomX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CytomX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CytomX Therapeutics backward and forwards among themselves. CytomX Therapeutics' institutional investor refers to the entity that pools money to purchase CytomX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-06-30 | 1.2 M | Congress Park Capital Llc | 2024-06-30 | 1.2 M | Superstring Capital Management Lp | 2024-06-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 769.5 K | Two Sigma Investments Llc | 2024-06-30 | 661.9 K | Adar1 Capital Management Llc | 2024-06-30 | 572.2 K | Citadel Advisors Llc | 2024-06-30 | 494.6 K | Sei Investments Co | 2024-06-30 | 382.7 K | Tang Capital Management Llc | 2024-06-30 | 7.8 M | Hhg Plc | 2024-06-30 | 6.3 M |
CytomX Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytomX Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytomX Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytomX Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CytomX Therapeutics Outstanding Bonds
CytomX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CytomX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CytomX bonds can be classified according to their maturity, which is the date when CytomX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.